C-6KXALadder Bio
Spiroligomer molecules, synthetic peptides, targeted drug discovery
small molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6KXA
C-6KXAC-6KXASpiroligomer molecules, synthetic peptides, targeted drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Securing Investment in Biotech Requires Clear Communication | Mohammad Arastoo posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … deadlines and prioritize two fit awards; assign one team member to manage each proposal timeline. 2. Design modular budgets with scalable milestones so a single grant can seed staged experiments and attract follow-on funders. 3. Target disease-specific foundations; request LOIs early, tailor aims to their patient-impact metrics, and ask for feedback. Use these steps together to create momentum and demonstrate rigorous stewardship to funders. In Philadelphia these practices a … , Cancer & Neuroscience | Prev-Bosch Health Campus, Maximon, Longevity Tech Fund 1mo I’m heading to Swiss Biotech Day organised by Swiss Biotech Association representing three lenses of the biotech stack: company-building, ecosystem, and capital. Infinity Biosciences GmbH is currently fundraising and developing strategic partnerships, and I’m also joining as part of: VitaDAO (DeSci longevity ecosystem) and Wild Tree Ventures (investing in breakthrough life science teams).
Brigid Bio Tackles Drug-Resistant Fungal Infections with Novel Monoclonal Antibody | Scottish Enterprise posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Con … ~4 million with an international consortium, led by the investor Collaborative Fund, with participation from EIFO (Danish Export and Investment Fund), and True, as co-investors. The pioneering biotech company Cambiotics, founded with support from Cambridge Enterprise and the BioInnovation Institute (BII) , is developing next-generation health solutions, built on findings from the Patil lab that certain species of gut bacteria can take in and store per- and polyfluoroalkyl su … n Pipeline (ICP) program recognizing biohealth companies across Wisconsin. "Our grant is to help us cover intellectual property expenses to help us protect our innovative approaches to help people rediscover strength and mobility," VibeTech CEO and Founder Jeff Leismer said following the award announcement. VibeTech is dedicated to improving health by assisting people dealing with motor system, balance and mobility challenges through the use of therapeutic vibration technolog
Ladder Bio Inc. Secures $5.5M Seed Financing | BYTE51data posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn … ~4 million with an international consortium, led by the investor Collaborative Fund, with participation from EIFO (Danish Export and Investment Fund), and True, as co-investors. The pioneering biotech company Cambiotics, founded with support from Cambridge Enterprise and the BioInnovation Institute (BII) , is developing next-generation health solutions, built on findings from the Patil lab that certain species of gut bacteria can take in and store per- and polyfluoroalkyl su … Florida Commerce, the Executive Office of the Governor, the Florida Opportunity Fund, and the State University System of Florida to discuss opportunities around biotechnology development, research collaboration, investment pathways, and long-term economic impact. At Vilin Bio Med, we strongly believe that meaningful partnerships between industry, government, and academia are essential to accelerate innovation in biologics, peptides, and advanced healthcare solutions. Grateful
--> Home | Molecule To Market top of page Register Agenda Sponsor Venue Info 2026 Media 2026 Panel Recaps Register Molecule to Market Museum of the American Revolution June 10th, 7:45-11:45 AM Philadelphia, PA The Essential Conference for Growing Biotech Firms Register Now Hosted at the Museum of the American Revolution, Molecule to Market 2026 celebrates the bold spirit that has defined Philadelphia for 250 years. Against this historic backdrop, we’re finalizing an exciting lineup of speakers and panels that spotlight the people, places, and innovation shaping Philadelphia’s life sciences clu
Ladder Bio featured in PBJ, raises $5.5M for Spiroligomer therapeutics | Ladder Bio Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Privacy Statement & Cookie Policy - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Website Privacy Policy and Cookie Policy Last modified: August 20, 2024 Introduction ThirdLaw Molecular Inc. and its affiliated entities (collectively the “Company” or “We”) respect your privacy and are committed to protecting it through our compliance with this policy. This policy descr … dicated non-browser-based interaction between you and this Website. It does not apply to information collected by: Us offline or through any other means, including on any other website operated by Company or any third party; or Any third party including through any application or content (including advertising) that may link to or be accessible from or through the Website. Please read this policy carefully to understand our policies and practices regarding your information an … ss, including to respond to any government or regulatory request. To enforce or apply our terms of use and other agreements, including for billing and collection purposes. If we believe disclosure is necessary or appropriate to protect the rights, property, or safety of the Company and our employees, contractors, agents representative, officers, directors, customers, or others. This includes exchanging information with other companies and organizations for the purposes of fra … legal or similarly significant effects. To exercise any of these rights please submit a request to [email protected] Nevada provides its residents with a limited right to opt-out of certain personal information sales. Please contact us at [email protected] if you are a Nevada resident and wish to learn more. However, please know we do not currently sell data triggering that statute’s opt-out requirements. Data Security The safety and security of your inform
Founder Lodge | Ladder Bio Inc. raises $5,500,000 at Seed on 2025-11-13 Daily News Rounds Investors Founders Benefits FAQ Memberships Log In Latest Viewed Log In --> 3 Latest Announced Rounds Forage | $40,000,000 | (Jun 5, 2026) InCharge Energy | $46,000,000 | (Jun 5, 2026) Oak Hill Bio | $32,500,000 | (Jun 5, 2026) Forage $40,000,000 Series B 5 Investors Financial Services Jun 5th, 2026 InCharge Energy $46,000,000 Unknown 2 Investors Services for Renewable Energy Jun 5th, 2026 Oak Hill Bio $32,500,000 Series A 3 Investors Biotechnology Jun 5th, 2026 $0.00M Raised in 0 Funding Rounds in the pa … artner at Medical Excellence Capital (MEC), an early-stage life science venture fund that leverages a global network of medical experts, family offices, and academic institutions to invest in innovative and impactful biotech and precision health technologies. I have personally co-founded, launched, and led several successful healthcare companies, including RightCare Solutions, a digital health company that was acquired by naviHealth, and Upward Health, a tech-enabled care del
Ladder Bio | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Category Ladder Bio May 19 Love 0 Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors By Frank DeMaria Portfolio News , Ladder Bio Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.--(BUSINESS WIRE)--Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new clas
Ladder Bio | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Ladder Bio Ladder Bio is pioneering a new therapeutic class – structured “ladder-shaped” spiroligomer molecules that bring biologic-level selectivity to targets once considered unreachable, while retaining the stability, oral availability, and modular tunability of small molecules. Categories Active View Project Ajaya Bio Agnos Therapeutics © 2024 BioAdvance. All Rights Reserved. | Privacy Policy | Site by Loudm
Board of Directors - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy J. David Owens Director David is the President & CEO of BiologicsMD, an early-stage drug development company, and a Founding Partner for Bowman’s Tower Venture Partners, a venture capital group founded in 2022 to assist entrepreneur leaders in advancing their early-stage life-science companies. Previous roles … investor since 2009 and was previously a member of the Mid-Atlantic Angel Group Fund II and the Delaware Crossing Investor Group. Dr. Barry Arkles Director Dr. Barry Arkles has a record of accomplishment in applied materials science, surface chemistry and biotechnology both from the innovation and managerial perspective that can be noted in contributions to a variety of applications including thermoplastic composites, the NASA Space Shuttle, Contact Lenses, Interlayer Dielect … ry. He has received numerous awards including the John Scott Medal, ACS Kipping Award in Silicon Chemistry, the R&D 100 Award for contributions to semiconductors. Board of Directors Dr. Barry Arkles Director J. David Owens Director Spiroligomer™ Molecules – Reimagining Peptides Discover more about Spiroligomer™ molecules Follow Follow Terms of Use Privacy Policy and Cookie Policy FCOI Policy Contact us © 2026 Ladder Bio Inc Site by Verb We use cookies to ensure that
Contact - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Contact If you would like to learn more about Ladder Bio, or our Spiroligomer™ platform, we would love to hear from you. Name (Required) First Last Email (Required) Enter Email Confirm Email Comments (Required) Please let us know what's on your mind. Have a question for us? Ask away. Ladder Bio 512 E. Township Line Roa
This team is going to change how we design and deliver new drugs. I’m excited to join Christian Schafmeister and the entire Ladder Bio Inc. team as we build something fundamentally new. Medical… | Eric Heil LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
#innovation #venturecapital #foundations #resilience #entrepreneurs #lifesciences #biotech #startups #entrepreneurship #innovation #nondilutivefunding #venturecapital #healthcareinnovation… | Michael Adler LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time
Ladder Bio Launches With $5.5 Million Seed Financing | Pulse 2.0 posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Alabama Life Sciences Economic Development Strategy | Project Catalyst: An Economic Development Podcast posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont
"Interview with Harsh Thakkar on undruggable proteome" | Ladder Bio Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
ThirdLaw Molecular: breaking barriers with Spiroligomer molecules | Christian Schafmeister posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Portfolio News Ladder Bio Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors By Frank DeMaria May 19, 2026 No Comments Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.–( BUSINESS WIRE )– Ladder Bio, Inc ., a structure-g … rtisan organization through which senior business and national security leaders apply private-sector expertise to critical U.S. defense and homeland security priorities. To date, Ladder Bio has secured more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency (DTRA), supporting the continued development of the company’s platform for biodefense, pandemic preparedness, and broader biosecurity applications. “ … medicines,” said Dr. Fine. “There are substantial opportunities to apply this differentiated platform to validated immunology targets and beyond. I am pleased to join the Board and to help the team translate this pioneering science into medicines for patients.” “Ladder Bio represents the type of platform innovation that can simultaneously reshape therapeutic development and strengthen national biosecurity preparedness,” said Mr. Prufeta. “The company’s comb
--> Where Are They Now? P | bluewhitescholarship top of page Log In Blue White Scholarship Foundation Donate 501(C)(3) - Tax ID 23-3095631 Testimonials Application Home Update About Us About Board of Directors Our Team Board Emeritus 2014 - Present Photo Gallery Ben Franklin Pledge '23 Linvilla Orchards '23 Pet Blessing Ceremony '23 Christmas Cheer Baking '23 Homecoming Tailgate '23 Scholars Where Are They Now? Benjamin Franklin Pledge Scholar Circumstances Donate Now Stock Wills & Trusts Others Ways to Give Auction Item Corporate Sponsorship IRA/ Lif … ONS Director & Editor The WorkShop Content Studios Cleveland, OH BLUE WHITE SCHOLARSHIP FOUNDATION P.O. Box 412 - Villanova, Pennsylvania 19085 - (610) 519-0777 Home About Us Events Scholars Donate Get Involved Blue White Blog Privacy Policy The Blue White Scholarship Foundation is a private 501 (c) (3) non-profit organization that is not affiliated with VILLANOVA UNIVERSITY ®. The following words are marks registered with the United States Federal Patent and Trademar … pyright and may not be copied or reproduced. © 2017 -2026 Blue White Scholarship Foundation bottom of page
Ladder Bio Number Of Employees Instagram Log In Sign Up Ladder Bio Number Of Employees Watch reels about ladder bio number of employees from people around the world. maxoklymenko Verified views 5M Ep. 502 - Career Ladder 🪜 He has a new office job? 💼 AD @tryramp 💪 #careers #careeradvice #business #careerladder #jobs maxoklymenko Verified views 2.8M Ep. 433 - Career Ladder 🪜 He just RETIRED from his job? 💪 #careers #careerladder #careeradvice #interesting #jobs maxoklymenko Verified views 18.4M Ep. 413 - Career Ladder 🪜 Toto’s first job is unguessable? 🏎️ #careerladder #careers #interesti
Therapeutics - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Challenges with Conventional Therapeutics Small molecules have been a traditional source for drug discovery due to their ease of maufacture through chemical synthesis, predicatable pharmacokinetics, oral bioavailability, and cell permeability enabling access to intra- and extra-cellular target proteins. They can lack s
Novel Drug Modalities | Discovery on Target | Sept 28-Oct 1, 2026 About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery Travel Posters Po … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press Novel Drug Modalities Tackling Difficult-to-Drug Targets with Glues, Chimeras, Condensates, Conjugates, Peptides 29 September - October 1, 2026 ALL TIMES EDT The application of innovative design and screening technologies—including artificial intelligence and machine learning (AI/ML)—is rapidly expanding the accessible che … a deep dive into preclinical data from Protai's KAT6 degrader program. 11:35 AM Application of AI and High-Throughput Proteomics for Molecular Glue Discovery Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine , Director , Biochemistry & Molecular Pharmacology , Baylor College of Medicine We will discuss how we apply state-of-the-art high-throughput proteomics to discover molecular glue hits and apply AlphaFold 3-like folding softw … scovery that does not require the synthesis of extremely large libraries and an application of this technology to the creation of phosphatase recruiting chimeras (PHORCs) that engage the PTP1B phosphatase. 2:50 PM Industrializing Molecular Glue Discovery Amine Sadok, PhD, Senior Director & Head of Induced Proximity Platform, Amgen Inc. , Senior Director & Head , Induced Proximity Platform , Amgen Inc. We are industrializing molecular glue discovery to drug previously … s, connect with peers, and turn in your Game Cards for a chance to win a raffle prize. VC Panel INSIGHTS FROM VENTURE CAPITALISTS Panel Moderator: 4:50 PM PLENARY PANEL DISCUSSION: Venture-Capitalist Insights on Trends in Drug Discovery Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer ,
2025 Annual Report - New Members | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Welcome New Members NEW MEMBERS Life Sciences PA is committed to building a membership that is diverse but shares a common goal of advancing the industry. We were proud to we … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
Ladder Bio, Inc. | Life Sciences PA Close Who We Are About Us Meet Our Team Board of Directors Membership Membership Benefits Become a Member Member Directory Member News Advocacy The Voice for PA’s Life Sciences Policy Priorities Our Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Member Login Industry News Contact Us Who We Are About Us Me … Partners Action Center Life Sciences Events Events Calendar Overview of Events Submit Your Event to LSPA Sponsorship & Volunteer Opportunities Life Sciences Future 2026 Photo Gallery Podcast Resources Economic Impact Annual Report Purchasing & Savings Life Sciences Center Quarterly Newsletters Ladder Bio, Inc. Back to Search Ladder Bio, Inc. http://www.LadderBio.com About Ladder Bio is a therapeutics company developing SpiroligomerTM ladder-shaped peptide-like mole … they need to succeed. $ Life Sciences Events Events Calendar Overview of Events Submit Your Event Sponsorship & Volunteer Opportunities Life Sciences Future Photo Gallery The Voice for PA's Life Sciences Through public policy advocacy in Harrisburg and Washington, D.C., Life Sciences PA serves as the voice for more than 960 member organizations across Pennsylvania that are critical to improving patient care, improving health globally, and to the economic growth of the Com
FCOI Policy - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy THIRDLAW MOLECULAR INC. CORPORATE POLICY FINANCIAL CONFLICTS OF INTEREST POLICY (TLM-FIN-01) SECTION 1. SCOPE The purpose of this policy is to promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research occurring at ThirdLaw Molecular … I and any other person identified as senior/key personnel by the Company in the grant application, progress report, or any other report under this FCOI Policy. “SFI Disclosure Form” means the disclosure form and accompanying documentation that an Investigator or individual must submit to the Company disclosing any SFI. “Significant Financial Interest” or “SFI” means: A Financial Interest consisting of one or more of the following interests of the Investigator and the Investig … ed to the Investigator’s company responsibilities: No later than at the time of application for research; At least annually during the period of the award or research project; and Within 30 days of discovering or acquiring a new SFI. The Company shall designate one or more Company Official(s), to solicit and review disclosures of SFIs of the Investigator (and those of the Investigator’s Immediate Family) related to an Investigator’s company responsibilities. The Company shall … g Investigators; At least annually (at the same time the Company is required to submit the annual progress report, multi-year progress report, if applicable, or at time of extension) to provide the status of the FCOI and any changes to the Management Plan, if applicable, until completion of the project; and Following Retrospective Review to update a previously submitted report, if appropriate. The authorized Official shall notify the Awarding Sponsor promptly if, during a Ret … , conduct or reporting of PHS-funded research and to include the requirement to submit a Mitigation Report in accordance with the Regulation. The procedures must include all Mitigation Report reporting elements as required by the Regulation. The authorized Official shall notify the Awarding Sponsor promptly if an Investigator fails to comply with
ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer - intelligence360 Toggle navigation intelligence360 About us Video News Daily Contact Us Search Icon intelligence360 The Intelligent News Source ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief … y Commercial Financing Commercial Relocation Executive Changes Federal Contract Award Mergers and Acquisitions (M&A) Sales and Marketing Innovation Uncategorized Venture Capital Recent Posts Ember LifeSciences has raised $27 Million in new Series A funding June 26, 2026 Relay Financial Technologies has raised $50 Million in new funding June 26, 2026 Forage has raised $40 Million in new Series B funding June 26, 2026 PhoenixAI has raised $80 Million in new Series B funding
ThirdLaw Molecular’s Senior Biologist to Present at SLASEurope 2025 as Part of Elite Innovation AveNEW Selection - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy ThirdLaw Molecular’s Senior Biologist to Present at SLASEurope 2025 as Part of Elite Innovation AveNEW Selection May 7, 2025 Share Media Contact: Alison Guzzio 484-459-3243 [email protected] Philadelphia, PA – … tion has been selected as part of the prestigious Innovation AveNEW program, an award that recognizes disruptive scientific innovation and provides full sponsorship for participation. “At ThirdLaw Molecular, we are redefining drug discovery with our breakthrough Spiroligomer™ platform, offering a new therapeutic modality that bridges the best of small molecules, biologics, and cyclic peptides. With our powerful SYMBA-DEL screening engine and a growing pipeline of validated hi
Hatch Bio Fund Portfolio Companies & Investment Focus | InvestorMatch.pro Investor Match How It Works Pricing Explore Investors For Investors Blog About VC Firms Hatch Bio Fund HA Hatch Bio Fund VC San Diego, CA Website How to approach: cold outreach ok Start a Campaign Explore Similar Investors Stage Pre-Seed, Seed Check Size $500K – $3.0M AUM $50M Portfolio 10+ companies Team 4 partners Investor activity Last known investment: 2017 Investments in last 12 months: 0 Investment Thesis Focuses on early-stage biotech companies transforming health through innovative technology. Meet the Team L … tors Seed Investors All VC Firms Frequently Asked Questions What does Hatch Bio Fund invest in? What stage does Hatch Bio Fund invest at? What check size does Hatch Bio Fund write? What sectors does Hatch Bio Fund invest in? Does Hatch Bio Fund accept cold outreach? Who are the partners at Hatch Bio Fund? What has Hatch Bio Fund invested in recently? See if Hatch Bio Fund is a match for your startup Upload your pitch deck to see how well you match with Hatch Bio Fund and 200+ … old. Double opt-in connections only. No spam, ever. All VC Firms > Hatch Bio Fund Hatch Bio Fund Portfolio Companies & Investment Focus Location: San Diego, CA Stage Focus: Pre-Seed, Seed Industry Focus: Healthcare, Other, SaaS Check Size: $500K - $3.0M Last investment: 2017 Investment Thesis Focuses on early-stage biotech companies transforming health through innovative technology. Partners at Hatch Bio Fund Lorenzo Pellegrini, Ph.D. — Managing Partner Timothy M … tide-mimetic / synthetic biologics) Genome Medical (Genomic Medicine) Hatch Bio Fund is Featured In Pre-Seed Investors SaaS Investors Seed Investors Healthcare Investors See if Hatch Bio Fund is a match for your startup on InvestorMatch.pro
Latus Bio Announces Multiple Oral and Poster Presentations | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Portfolio News Latus Latus Bio Announces Multiple Oral and Poster Presentations By Gayle Mineo April 29, 2025 May 27th, 2025 No Comments Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting PHILADELPHIA–( BUSINESS WIRE )– Latus Bio Inc. (Latus) , a biotechnology company pioneering … oGenesis Expands Phase 1a/b Trial of IMGS-001 Next Post Strados Labs Introduces Grant Initiative Comments are closed. --> Share Share Share Share Pin © 2024 BioAdvance. All Rights Reserved. | Privacy Policy | Site by Loudmark 101 West Elm Street, Suite 330, Conshohocken, PA 19428 | (610) 230-0544 Close Menu About Team Portfolio News Contact linkedin patreon
Jobs at Ladder Bio | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
RightCare Solutions, a Startup Based on Penn Nursing Research, Wins the Janssen Connected Care Challenge - News Skip to content Skip to main menu Faculty Youth Program Undergrad Jacobs MSQF MBA EMBA PhD Exec Ed Wharton Online Search Wharton Mobile menu toggle News Menu Press Releases Seminars for Business Journalists Wharton Faculty Op-Eds Podcasts Resources Contact Us RightCare Solutions, a Startup Based on Penn Nursing Research, Wins the Janssen Connected Care Challenge Kathryn Bowles and Eric Heil, WG'12, of RightCare Solutions present on D2S2 at the Janssen Connected Care Challenge. PH … Nursing , is the winner of the Janssen Connected Care Challenge and a $100,000 prize, awarded by Janssen Healthcare Innovation , part of Janssen Research & Development, LLC. D2S2 helps health-care providers reduce hospital re-admission by assembling and scoring key data upon hospital admission to identify patients who should be referred to post-acute-care services upon discharge. D2S2 was developed by a multi-disciplinary team of researchers at the NewCourtland Center fo … zing technologies and intellectual property. “We are honored to receive the top prize of the Janssen Connected Care Challenge for D2S2,” Heil said. “We are looking forward to applying the award to further advance our product and ultimately improve patient care.” A panel of judges selected D2S2 as the winner from more than 100 submissions to the Challenge. Kimberly Park, founding partner of Janssen Healthcare Innovation, presented the $100,000 prize to Heil at the Wireless Hea … discharge-planning process, which is highly variable.” In addition to the main prize, D2S2 was also recognized with a $50,000 award for being one of the top three finalists in the Challenge. In addition, last month, RightCare Solutions earned a $30,000 prize as the winner of the Wharton Business Plan Competition . D2S2 is based on a decade of research by the Bowles team. A successful first case study at a major academic hospital demonstrated a significant reduction in 30-day … the D2S2 so our patients get the right care and achieve improved outcomes.” The prize money will support the build-out of the D2S2 software and additional studies at four hospitals. Via University Communications May 29, 2012 | Press Releases Back To Top Additional Links News Press Releases Seminars for Business Journalists Wharton F
Portfolio - Hatch Biofund skip to main content Investment Focus Partners Portfolio News Contact Investment Focus Partners Portfolio News Contact Portfolio Our portfolio companies are working hard every day to bring new hope to patients with uncurable diseases. Hatch BioFund is proud to have been chosen to invest in them. Optimeos Life Sciences has developed a highly differentiated, non-viral nanoparticle drug delivery platform based on a patented process refined over two decades in the laboratory of Princeton University Professor Robert Prud'homme. The technology enables the robust, scalable e … sity of Pittsburgh and the University of Pennsylvania, co-founded by 2023 Nobel Prize laureate in Physiology or Medicine Dr. Drew Weissman. The Company has developed a modified mRNA therapy targeting Hepatocyte Nuclear Factor-4 alpha (HNF4α), the master transcriptional regulator of hepatic function, for the treatment of End Stage Liver Disease with cirrhosis. In multiple cirrhotic disease models, upregulation of HNF4α restores expression of downstream proteins critical to hep
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Portfolio News Vittoria Biotherapeutics Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting By Webmaster December 9, 2024 December 10th, 2024 No Comments Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies Data
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
ThirdLaw Molecular | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies ThirdLaw Molecular ThirdLaw Molecular LLC (branded online as Ladder Bio) is a drug-discovery and diagnostics company founded in 2020 to develop a novel class of chemically synthesized, structured oligomeric macromolecules for targeted therapeutics and diagnostic reagents. The organization designs and synthesizes large combinatorial libraries (including DNA-encoded libraries), applies computational molecular design and high-throughput screening to identify pr
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Entrepreneur Spotlight Panelists - PA Bio Center Menu Blumberg Institute Hepatitis B Foundation Hep B Stories Menu Contact Us (215) 589-6300 Invest Donate Menu Home About About Us Mission History Leadership Economic Impact B+labs Facilities & Services Open Lab and Office Space Amenities Community Community Overview Strategic Partners Members Become a Member BioLaunch 360° Careers PABC Store Make A Payment PABC Videos Education News & Events News Calendar of Events Signature Events Golf Outing Regional Biotechnology Conference Entrepreneur Spotlight Biotech Insiders Podcast Our Newsle … er at Medical Excellence Capital, LLC, a $150M early stage life science venture fund founded by patients for patients. He holds board positions at Nobias Therapeutics and GC Therapeutics and is the co-founder and board chair of ProJenX, a company focused on therapies for brain diseases like ALS. He also serves as a board advisor to the Medical Excellence Foundation, a 501c3 non-profit organization, and is an active member of the Faith-Driven Investor movement. Prior to his cu … ment professional at Domain Associates, LLC, the oldest biotech focused venture fund in the country. Eric’s academic background includes a bachelor’s in systems engineering from the University of Pennsylvania and an MBA from Wharton. He currently resides in Bucks County, PA with his family of 5 children. Kathie Jordan, PhD Managing Director at Ben Franklin Technology Partners Kathie Jordan is the managing director of the Healthcare Investment Group at Ben Franklin Technology … the Coulter-Drexel Translational Research Partnership, an endowed non-dilutive fund of health care technologies, ranging from small molecule therapeutics to medical devices and diagnostics. Technologies that were initially supported by the program have been licensed to over a dozen startups, with multiple products now on the market. Prior to joining Drexel, she was the director of the Coulter program at the University of Washington, where she also worked in the technology tr
19. Prof. Christian Schafmeister: Developing Synthetic Therapeutic Catalysts to Correct Diseases of Aging (INTRO) — RAADfest 0 Skip to Content Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Speakers 2022 Speakers About FAQ Contact Us Register for 2026 Open Menu Close Menu Register for 2026 Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Sp
The Third Way: Christian Schafmeister’s Spiroligomer Revolution Mendelspod Subscribe Sign in Mendelspod Podcast The Third Way: Christian Schafmeister’s Spiroligomer Revolution 1 1 1× Preview 0:00 Current time: 0:00 / Total time: -4:18 -4:18 Audio playback is not supported on your browser. Please upgrade. The Third Way: Christian Schafmeister’s Spiroligomer Revolution Theral Timpson May 22, 2025 ∙ Paid 1 1 Share For decades, drug discovery has followed two main roads: small molecules that can slip into cells but often lack precision, and biologics that offer specificity but struggle with delive
Happy to announce Dr. Christian Schafmeister as a speaker for our 2020 Undoing Aging Conference – Lifeboat News: The Blog Skip to content Lifeboat Foundation: Safeguarding Humanity About Blog Boards Programs Reports Papers Donate Join Us Newsletter Quotes Store Press Releases Toggle sitemap Lifeboat Foundation Sitemap icon-search Main Areas Home About Boards Blog Programs Reports Papers Donate Join Us Newsletter Quotes Store Press Releases Current Programs AIShield AsteroidShield BioShield InfoPreserver InternetShield LifePreserver LifeShield Bunkers NanoShield ScientificFreedomShield Se … ficFreedomShield SecurityPreserver Space Habitats X-Risks Network Cool Places A-PRIZE Ark I Blue Beauty EM Launch GETAS Official Song Working Together A-500 Banners Events FightAIDS@Home Folding@Home Forums HQ Supervisor Lifeboat 500 Links Openings Outreach Partnerships Rosetta@Home Volunteer Work About Us Bitcoin Endowment Fund Boards Board of Directors Contact Us Donor List FAQ Finances Guardian Award Interactive Friendly AI Logo Memorial Board Mission Statement Procedures
American Chemical Society Skip to main content Christian Schafmeister Appearances × Evaluation Close Print Submit
Christian Schafmeister - 2018 LLVM Developers' Meeting Sched.com Conference Mobile Apps 2018 LLVM Developers' Meeting has ended Create Your Own Event 2018 LLVM Developers' Meeting Schedule Speakers Attendees Search Menu Schedule Speakers Attendees Search Share your event Share via or Copy link Copy ← Back Christian Schafmeister Temple University https://chem.cst.temple.edu/schafmeister.html About me I'm a professor of Chemistry developing large molecules to solve real-world problems. We have developed a software environment (Cando) for designing these molecules that implements a
Happy to announce Dr.... - Lifespan Research Institute Facebook Log In Lifespan Research Institute's Post Lifespan Research Institute February 18, 2020 · Shared with Public Happy to announce Dr. Christian Schafmeister as a speaker for our 2020 Undoing Aging Conference. Christian Schafmeister, Ph.D., Professor at Temple University in Philadelphia says: “We are developing "therapeutic catalysts" - small, robust, non-immunogentic catalysts that will permeate the tight spaces within tissues and fix things. Our specific targets include reversing the unwanted cross-links that develop
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Merck Invests In Pan-canadian Life Sciences Research Innovation Sector | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Keynote Speakers - Bucks County Book Festival - Experience Yardley Skip to content Facebook Instagram DONATE NOW Facebook Instagram DONATE NOW Close HOME CALENDAR Visit Yardley EXPLORE THE BORO HISTORICAL YARDLEY LANDMARKS OUT IN NATURE WHAT WE DO MUSIC OFF MAIN RESTAURANT WEEK Canal-O-Ween™ WHO WE ARE WHO WE ARE OUR SPONSORS FAQ’s DONATE CONTACT US Community Calendar « All Events This event has passed. Keynote Speakers – Bucks County Book Festival May 4, 2025 @ 4:00 pm - 5:00 pm « Weekly Meditation/Dharma Talk Party on the Porch » Join us on Sunday, May 4th, at 4 pm at … 25 Bucks County Book Festival’s thrilling capstone event, where bestselling and award-winning author Laurie Halse Anderson will sit down with YA and adult contemporary romance writer Nisha Sharma to discuss her books, career, and future plans. This is a ticketed event. All packages include at least one copy of Laurie’s latest book Rebellion 1776 . Additional titles by both authors will be available for purchase at the event. To learn more about the event and buy tickets, clic
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
WEDTalks | Bucks County, PA Skip to Main Content Search Government Courts Living Working Visiting How Do I... Home Government Departments Workforce & Economic Development PA CareerLink® Bucks County WEDTalks WEDTalks Would you like to learn more about trending workforce topics that impact employee retention and engagement, effective leadership, filling the skill gap, and more? How do these topics affect your business, the success of employees, or your own career success? Join us for WEDTalks to find out! WEDTalks are free monthly virtual masterclasses in timely, purposeful, and expertly curate
Each week, we share stories of those whose service strengthens the fabric of our community. This week, we remember and honor a dear friend, trusted partner, and visionary leader—Linda Salley of Levittown, whom we sadly lost last week. Linda was one of our first Hometown Heroes, and for good reason. There are some people whose work does more than serve a community. It enlarges it, deepens its memory, and leaves behind a light by which others may find their way. Linda was such a person. A gifted educator, lifelong learner, and devoted woman of faith, Linda dedicated her life to the belief that e
--> --> Ignite Bucks Area - Blue Zones About Us About Us Original Blue Zones Explorations Our Culture Our Research Resources Articles News Recipes Live Better, Longer Services & Solutions All Services and Solutions Where We Work Blue Zones Health Careers Shop Store Meal Planner Blue Zones Kitchen Blue Zones x Immunocologie Get In Touch About Us About Us Original Blue Zones Explorations Our Culture Our Research Resources Articles News Recipes Live Better, Longer Services & Solutions All Services and Solutions Where We Work Blue Zones Health Careers Shop Store Meal Planner Blue Zones K
Pennsylvania House Speaker Joanna McClinton to Headline NAACP Bucks County’s Women’s History Month Town Hall in Newtown - Bucks County Beacon Level Up Your Inbox Facebook-f Instagram Youtube Threads Tiktok Support the Beacon Search News Education Elections Opinion Culture The Signal News Education Elections Opinion Culture The Signal Events , News Pennsylvania House Speaker Joanna McClinton to Headline NAACP Bucks County’s Women’s History Month Town Hall in Newtown The event, “Women Who Lead: Power, Representation & The Future of Justice in Pennsylvania,” will take place Monday at Bucks Co
--> Keynote | Bucks County Book Festival top of page Who We Are Contact Committee News Coverage Gallery Past Events Donate More Use tab to navigate through the menu items. Keynote Join us for an unforgettable evening with bestselling author Tessa Bailey in conversation with Nisha Sharma at the Bucks County Book Festival’s Keynote Event! Held at Salem Church in Doylestown, this special event will celebrate the power of storytelling, creativity, and literature. Enjoy an engaging discussion, participate in a live Q&A, and get their latest books. Buy Tickets event Details Join us o … ks County Book Festival’s thrilling capstone event, where bestselling and award-winning author Tessa Bailey will sit down with YA and adult contemporary romance writer Nisha Sharma to discuss her books, career, and future plans. This is a ticketed event. All packages include at least one copy of Tessa’s latest book Catch Her If You Can: A Novel . Additional titles by both authors will be available for purchase at the event. Doors open at 6:00 pm and the even … sp; TICKETS No events at the moment Email Yes, subscribe me to your newsletter. Submit 2026 BUCKS COUNTY BOOK FESTIVAL bottom of page
LSC | Upcoming Speakers | Bucks County Free Library Webinars and Online Events Skip to main content Bucks County Free Library Home (current) Upcoming Speakers Past Speakers Library Home (opens in new window) FAQ (opens in new window) Library Admin Login (opens in new window) Advanced Search Advanced Search Upcoming Speakers Cooking/Food Fiction Health & Wellness K-12 Nonfiction Variety and Lifestyle Register for upcoming talks from bestselling authors and thought leaders. Brought to you in partnership with the Library Speakers Consortium. Small Towns and Big Secrets: In Conversation with B … n Cost of the American Dream and Healing Through Storytelling with Reyna Grande Award-Winning and Bestselling Author of The Distance Between Us and A Dream Called Home Thursday, July 16th 2026 at 2:00 PM EDT The Power of Connection: Creating Lasting Friendships in an Increasingly Lonely World with Dr. Marisa Franco Psychologist, Professor, and New York Times Bestselling Author Tuesday, July 28th 2026 at 2:00 PM EDT The Legacy of Julia Child's Kitchen with Smithsonian Cur … es Testify: Reclaiming America’s Black Botanical Legacy with Beronda Montgomery Award-Winning Plant Biologist and Author Tuesday, August 25th 2026 at 2:00 PM EDT High Altitudes and High Stakes: A Miss Marple Mystery with Lucy Foley #1 New York Times Bestselling Author of The Guest List and The Midnight Feast Thursday, August 27th 2026 at 2:00 PM EDT © 2015 to 2026 PBC Guru LLC, All rights reserved. Privacy Terms Accessibility Cookie Consent We use ess
Speaker Mike Johnson, Brian Fitzpatrick fundraise at Newtown estate Skip to main content Home Election Local Crime Education State Politics & Elections Unwell Water Special Reports The Unclaimed House Speaker Mike Johnson fundraises in Bucks County as midterms loom Jess Rohan Bucks County Courier Times Show Caption Hide Caption New upscale fine dining restaurant opens in Bucks County. See video The former Sycamore Grille has reopened as Mélange on Sycamore, an upscale restaurant featuring a cuisine of both Louisiana and Italian dishes. House Speaker Mike Johnson fundraised in Bucks Coun
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Vesigen Therapeutics Names Rakhshita Dhar to Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
EULAR2026: Future of Immunology and Patient Outcomes | Novartis Medical posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr
The Escalator: Genentech, Denali Therapeutics, Eli Lilly and more HAYMARKET MARKETING COMMUNICATIONS: Campaign US MM+M PRWeek Newsletters | Log In | Register Search for: News Agencies Five Things to Know Data/Analytics Campaigns Pharma Podcasts Policy Media Technology People Moves Rare Disease In-Depth MM+M Best Places to Work 2025 Career and Salary Survey 2025 Healthcare Marketers Trend Report 2025 MM+M/Publicis Health Innovation Survey 2025 Events MM+M Awards MM+M Media Summit AI Deciphered Pinnacle Awards MM+M 40 Under 40 2025 MM+M Transform MM+M Health Marketing Influencer 25 Women of Dist
SeaX Ventures at BIO Partnering for Oncology 2026 | SeaX Ventures posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … closed a $137 million Series B with Frazier Life Sciences and Novartis Venture Fund co-leading, advancing bispecific ADCs for solid tumors toward the clinic. 🔄 Crossover & Pre-IPO Activity: Aktis Oncology's $318 million IPO earlier this year has set a strong precedent for radiopharmaceutical and targeted oncology companies eyeing the public markets in H2 2026. Crossover appetite for differentiated clinical-stage assets with first-in-class potential remains firm heading … closed a $137 million Series B with Frazier Life Sciences and Novartis Venture Fund co-leading, advancing bispecific ADCs for solid tumors toward the clinic. 🔄 Crossover & Pre-IPO Activity: Aktis Oncology's $318 million IPO earlier this year has set a strong precedent for radiopharmaceutical and targeted oncology companies eyeing the public markets in H2 2026. Crossover appetite for differentiated clinical-stage assets with first-in-class potential remains firm heading
News | BioAdvance Capital Skip to main content Hit enter to search or ESC to close Search Close Search search Menu About Team Portfolio News Contact linkedin patreon search Latest News INSIGHTS & UPDATES Jun 22 Love 0 Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease By Gayle Mineo Portfolio News , Tolerance Bio BCI’s second investment to advance therapeutic treatments for celiac disease will support preclinical development of novel approach to immune tolerance AMBLER, PA, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- Beyond Ce … atus founder Beverly Davidson, Ph.D., awarded the ASGCT Outstanding Achievement Award – the Society’s highest honor PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today… Read More Apr 24 Love 0 What is shelf-stable synthetic blood? The scientific advancement that could transform battlefield and emergency care By Gayle Mineo Portfolio News , KaloCyte The Economic Times, U … od and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 3 clinical trial for IVIEW-1701. IVIEW-1701 is an innovative drug… Read More Feb 19 Love 0 Wellsheet continues momentum with health systems across US, brings AI to San Juan Regional Medical Center By Gayle Mineo Portfolio News , Wellsheet Becomes go-to AI intelligence layer and clinical decision support tool across 100+ hospitals NEWARK, N.J., Feb. 19, 2026 /
ThirdLaw Molecular in Drug Discovery News on cancer research innovations | Ladder Bio Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
%PDF-1.4 %���� 159 0 obj > endobj 161 0 obj >stream 2019-11-19T20:02:28-05:00 2019-11-22T14:23:03-08:00 2019-11-22T14:23:03-08:00 itext-paulo-155 (itextpdf.sf.net-lowagie.com) application/pdf Challenges and Approaches to Genotyping Repetitive DNA uuid:5ca7253f-1dd2-11b2-0a00-ca08279d9800 uuid:5ca7254b-1dd2-11b2-0a00-d20000000000 endstream endobj 151 0 obj > endobj 1 0 obj > endobj 2 0 obj >/MediaBox[0 0 612 792]/Parent 1 0 R/Resources >/ProcSet[/PDF/Text]>>/StructParents 0/Tabs/S/Type/Page>> endobj 3 0 obj >/MediaBox[0 0 612 792]/Parent 1 0 R/Resources >/Font >/ProcSet[/PDF/Text]>>/StructParen
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Bionow BioAI Summit 2026 | Bionow on Glue Up This is a past event. Registration is closed. View other Bionow events. EN English Log In Close Please enter a valid email address e.g. [email protected] Email Address * If you input more than 0 characters your Email Address may not display properly Afghanistan | 🇦🇫 + 93 Aland Islands | 🇦🇽 + 358 Albania | 🇦🇱 + 355 Algeria | 🇩🇿 + 213 American Samoa | 🇦🇸 + 1684 Andorra | 🇦🇩 + 376 Angola | 🇦🇴 + 244 Anguilla | 🇦🇮 + 1264 Antarctica | 🇦🇶 + 672 Antigua and Barbuda | 🇦🇬 + 1268 Argentina | 🇦🇷 + 54 Armenia | 🇦🇲 + 374 Aruba | 🇦🇼 + 2 … input more than 0 characters your New Password may not display properly Cancel Submit Your password has expired. Change your password to continue. Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number , and one special character(!"#$%&'()*+,-./\:;?@[]^_`{|}~=) . Close Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number, and one special chara … input more than 0 characters your New Password may not display properly Cancel Submit Email Address Not Found Please go to My Profile and add an email address to continue with this action. Cancel
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Machine Learning for Health (ML4H) | Broad Institute Skip to main content Top menu Careers Giving Intranet Search Show results from www.broadinstitute.org intranet.broadinstitute.org All About us This is Broad Learn about our mission, values, and history. Our impact Discover the impact of our research on human health. Our focus areas Learn about Broad’s main areas of research. People Meet our members, staff scientists, fellows, leadership, and other Broadies. Join Broad Find out how to join the Broad as an employee or associate member. Contact us Find our contact information, directions to our … ad_ml4h on X or join our mailing list . Latest news News 06.15.2026 2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant News 06.15.2026 Scientists improve nearly every aspect of prime editing, moving it closer to treating more genetic diseases News 05.13.2026 Precision DNA editing targets root cause of severe childhood epilepsy in preclinical study News 05.01.2026 Single-molecule tracker illuminates workings of cancer-related proteins
#neurips #ml4h #machinelearning #ai #digitalpathology #hiring #pathai | PathAI LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Ag
Machine Learning for Health (ML4H): Advancing Healthcare for All NeurIPS 2020 CSP Test --> Skip to yearly menu bar Skip to main content Main Navigation NeurIPS Help/FAQ Contact NeurIPS Create Profile Code of Ethics Code of Conduct Journal To Conference Track Diversity & Inclusion Proceedings Future Meetings Press Exhibitor Information Privacy Policy Downloads My Stuff Login Select Year: (2020) 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Earlier Conferences Getting Started Schedule Featured Invited Talks Outstanding Paper Awards A … Beaulieu-Jones ⋅ Danielle Belgrave ⋅ Tristan Naumann Project Page Abstract The application of machine learning to healthcare is often characterised by the development of cutting-edge technology aiming to improve patient outcomes. By developing sophisticated models on high-quality datasets we hope to better diagnose, forecast, and otherwise characterise the health of individuals. At the same time, when we build tools which aim to assist highly-specialised caregivers, we limit
ML4H Home About History Past Events Organizing Committee Governing Board Sponsor Submit Call for Papers Call for Demonstrations Mentorship Programs Attend Schedule Speakers Research Roundtables Plan Your Visit Resources Writing Guidelines Reviewing Guidelines Community Guidelines Code of Conduct Review Policy Publication Ethic FAQs Job Board Home About History Past Events Organizing Committee Governing Board Sponsor Submit Call for Papers Call for Demonstrations Mentorship Programs Attend Schedule Speakers Research Roundtables Plan Your Visit Resources Writing Guidelines Reviewing Guidelines C … e Westin San Diego Gaslamp Aug 1: Submission site opens Sep 8: Paper submission deadline Oct 27: Decisions released Please direct any questions to [email protected] For announcements, follow us on Twitter @symposiumml4h 24 Speakers 2.5k Attendees 80 Awards Schedule Registration Sponsors Diamond Gold Silver Design & Developed by ThemesPride Back to Top
Biotech Founders Balance Science and Organization Building | Steve Curry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag … ientists, and operators about one of the harder questions in biotech: How do we fund platforms before the market fully understands why they matter? In deep biotech, funding is rarely just about money. It is about translation risk, technical credibility, timing, proof points, and whether a team can explain complex science without turning it into either a fairy tale or a 90 slide enzyme kinetics lecture. A concrete example: when you build a new way to manufacture pepteins, the
Supramolecular Therapeutic Peptide Platform Secures $12.5M Seed Round | Amphix Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … omments To view or add a comment, sign in More Relevant Posts CTI Life Sciences Fund 2,113 followers 5mo Report this post CTI Life Sciences Fund continues to deploy capital in areas of high unmet medical need in the neurology space, supporting the advancement of innovative, first-in-class therapeutic assets. The recently closed $10M Series A Extension financing for Find Therapeutics , alongside adMare BioInnovations and Investissement Québec , reflects our conviction in Tasro
MEC Portfolio Companies Make Big Moves at JPM | Medical Excellence Capital, LLC posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … re Copy LinkedIn Facebook X To view or add a comment, sign in CTI Life Sciences Fund 2,113 followers 5mo Report this post CTI Life Sciences Fund continues to deploy capital in areas of high unmet medical need in the neurology space, supporting the advancement of innovative, first-in-class therapeutic assets. The recently closed $10M Series A Extension financing for Find Therapeutics , alongside adMare BioInnovations and Investissement Québec , reflects our conviction in Tasro … release: https://lnkd.in/e_SVVeqk 📌 Applicant webinar: January 27, 2026 🗓 Pre-proposal deadline: March 16, 2026 🔗 Learn more: c-path.org/trxa #RareDisease #CASKgene #TherapeuticDevelopment #RareDiseaseResearch #caskresearch 12 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in ESMO - European Society for Medical Oncology 114,717 followers 4mo Edited Report this post Major headlines. Big hopes. Important clarifications. Recent preclinical results
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Attending BIO International Convention 2026 in San Diego | Mibell A. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … ic experts to join us at the Innovative Biotech Summit. Explore next-generation application of biotech concepts to alternative proteins, functional ingredients, agritech, and personal care at this collaborative, interactive event. ✅ Discover the newest industry trends and technologies. ✅ Share your experience and find solutions for scale‑up and innovation challenges. ✅ Learn from Sartorius capability showcases, case studies, and key industry partners. ✅ Participate in technol … es, case studies, and key industry partners. ✅ Participate in technology demos, application center tours, and interactive discussions. ✅ Enjoy dedicated networking sessions, including an informal dinner. Let’s connect, collaborate, and help to shape the next generation of biotech innovation. 👉 Register now: https://sar.to/57uvn #SimplifyingProgress #InThisTogether #Bioprocessing #Biotech 23 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in RJ Moll … J&J, Merck KGaA, and Biotech | Advisor to BIO, BTS, NCI, Myeloma Investment Fund and Others 1w BIO 2026 - San Diego I am honored to join the speaker lineup for the BIO International Convention 2026. This event is the heart of global biotech, where we bridge the gap between breakthrough science and meaningful human impact. I cannot wait to exchange ideas with the visionaries and leaders shaping the future of our industry. See you there! #BIO2026 #DrivenbyPurpose 4 1 Commen
#design #speed #drivenbypurpose #drugdiscovery #systems #spirologomers #design #deals #people | Ladder Bio Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … Prufeta Jay Fine David Scheer J. Todd Abrams Blandine Chantepie-Kari Rebecca L Grant, DVM Lorenzo Pellegrini, Ph.D. BIO International Convention 2027 comes home to Philadelphia in 2027. It’s going to another level!! Save the date now! Can’t wait! 59 2 Comments Like Comment Share Copy LinkedIn Facebook X Rebecca L Grant, DVM 1d Report this comment We believe in Ladder Bio and are grateful you’re in Philadelphia! So much more to come! Like Reply 1 Reaction Tomi Sawyer 1d
Team - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Prof. Christian Schafmeister Founder, Chief Technology Officer Christian is the CTO and Founder of Ladder Bio, and inventor of Spiroligomer™ molecules for drug and diagnostic innovation. He also serves as a Chemistry Professor at Temple University. An acclaimed AMBER software developer, Christian has been pivotal in advancing … elp launch Medical Excellence Capital, LLC, an early-stage life science venture fund founded by patients for patients. He currently holds board positions at Nobias Therapeutics, GC Therapeutics, Ladder Bio, and is the cofounder and board chair of ProJenX, an ALS company. In September 2025, Eric joined Ladder Bio as CEO. Prior to MEC, Eric cofounded and led two venture-backed companies as CEO, including Upward Health (partnered with BCBS Venture Fund) and RightCare (acquired b … professional at Domain Associates, LLC, a leading life-science venture capital fund with over $2.5 billion under management. During his tenure at Domain, Eric also led business development at portfolio companies Corthera (acquired by Novartis) and Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals). He began his career as a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry, and an Equity Research An … ations and patents and is the holder of many awards including a Merck Directors Award (1998); PhRMA Discoverers Award (1999); Intellectual Property Owners “National Inventor of the year Award” (1997); European Inventor of the Year (non-EU nation) (2007); ACS “Award for Creative Invention” (1999); and was a named a Merck Research Laboratories Presidential Fellow in 2008. He was named to the American Chemical Society Medicinal Chemistry Hall of Fame (Aug. 2012) and was also nam … a Distinguished Alumni Entrepreneur and has received a Professional Achievement Award from the Department of Chemistry & Biochemistry and the College of Science. Most recently, Tomi launched the Peptide Drug Hunter Consortium and the Saint Albert the Great Institute for Science, Faith & Wisdom. Dr. Marius Pop Vice President of Biology Mar
Ladder Bio's Goldilocks Molecules Revolutionize Medicine Delivery | Alison Guzzio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si
Novel Spiroligomer™ chemistry > AI-enabled structure-based drug design > Applications spanning therapeutics, biodefense, and pandemic preparedness With more than $16.9M in non-dilutive DoD and DTRA funding secured to date, Ladder Bio continues to position itself at the convergence of next-generation therapeutics and national biosecurity. See full release here: https://lnkd.in/es-ZZtsw #Biotech #DrugDiscovery #AI #Immunology #Oncology #Biosecurity #Biodefense #DrugDevelopment #BoardAppointments"> Novel Spiroligomer™ chemistry > AI-enabled structure-based drug design > Applications spanning ther
Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors May 19, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.--(BUSINESS WIR … rtisan organization through which senior business and national security leaders apply private-sector expertise to critical U.S. defense and homeland security priorities. To date, Ladder Bio has secured more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency (DTRA), supporting the continued development of the company’s platform for biodefense, pandemic preparedness, and broader biosecurity applications. "We ar … ynthesizable medicines," said Dr. Fine. "There are substantial opportunities to apply this differentiated platform to validated immunology targets and beyond. I am pleased to join the Board and to help the team translate this pioneering science into medicines for patients." “Ladder Bio represents the type of platform innovation that can simultaneously reshape therapeutic development and strengthen national biosecurity preparedness,” said Mr. Prufeta. “The company’s combinatio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Ladder Bio Inc. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute da … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Ladder Bio Inc. - overview Established 2020 Location Blue Bell, PA, US Primary Industry Biotechnology About Ladder Bio Inc. , based in the US, specializes in research and development of innovative Spiroligomer™ molecules designed for precise molecular interactions in therapeutics and diagnostics. Founded i … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Ladder Bio Appoints Jay Fine and John Prufeta to Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.7 %���� 1 0 obj >/Metadata 4951 0 R/ViewerPreferences 4952 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 720 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Vmo�0�^���>:��~��H�u 1[��!�]D_F�N�'�/�s��Sˢ��r��w�=w�e��I�Vp|>�_����R)A��F@��{_������ aZ�{�kea���=�ɳ~�c����`LJ�$E�⇽��~$��+�#��y2�,�,�߮NK�?��p�5\����$�ԡƇRPx[2� ��f���>�`yla4!�č$?:T %���hN���).�R f-z���i��20�B����2+������8��Oe��؇*���G�5����դa�%�n�p-��5_��ȓ)*.pF�*Ok���3IӬQ^5Bz/ɩ���7>�����j�|z���`���{=�$m�p
Ladder Bio Seed Funding Medical Excellence Capital Instagram Log In Sign Up Ladder Bio Seed Funding Medical Excellence Capital Watch reels about ladder bio seed funding medical excellence capital from people around the world. ladder medical fund skim.insights views 6,089 Generate Biomedicines is proving that the future of drug discovery won’t be found in a lab. It will be designed by algorithms. #startups #biotech #science #ipo #venturecapital no.fixed.rout... views 109 Hard to pull yourself out once you're in. We're going after deep-rooted solutions. Solve real problems, not just fe … ight now: Global drug development is global for a reason — cost. But government grant restrictions are pushing companies toward US-only CROs. And now with the companies of concern list just released? The urgency is real. The result? ✅ Preclinical budgets: DOUBLED ✅ IND-enabling studies: DOUBLED ✅ Companies forced to choose between compliance and capital efficiency ✅ Supply chain audits happening RIGHT NOW For early-stage biotech companies relying on government grants to build … ir story before going to investors, this is a nightmare. You either: → Take the grant and pay 2x for the same work → Or go offshore and lose access to funding For companies that haven't raised VC yet? This is existential. Dr. Elaine Hamm broke this down in Episode 1 of Open Door Salon — and with the list now public, it's hitting harder every day. 👀 Full episode link in bio #BIOSECURE #Biotech #DrugDevelopment #CRO #LifeSciences #BiotechStartups #Pharma #Innovation … nto known risks • Teams that move fast to eliminate uncertainty • Investors who fund execution, not theory Biotech doesn’t reward storytelling. It rewards people who can take risk off the table and deliver outcomes. 🎧 Episode live now. Join the conversation inside SCALE Community, where healthcare leaders engage directly with the guests shaping what’s next. 👉 www.scale-community.com #Biotech #HealthcareInnovation #LifeSciences #HealthInvesting #AnalyzingHealthcare #ScaleCom … nto known risks • Teams that move fast to eliminate uncertainty • Investors who fund execution, not theory Biotech doesn’t reward storytelling. It rewards people who can take risk off the table and deliver outcomes. 🎧 Episode live now. Join the conversation inside SCALE Community, where healthcare leaders engage directly with the guests shaping
Temple University spinout ThirdLaw rebrands as Ladder Bio with $5.5M funding | BioBuzz - Greater Philadelphia posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin … to protect and commercialise their ideas. 💡 From 1 July 2026, the policy will apply to most IP supported by funding from the science, innovation and technology portfolio, including the Marsden, Endeavour and Health Research funds. It ensures researchers have more control over the commercialisation of their inventions, with clear rules around ownership and equity sharing. https://lnkd.in/gipppFeD 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in … to protect and commercialise their ideas. 💡 From 1 July 2026, the policy will apply to most IP supported by funding from the science, innovation and technology portfolio, including the Marsden, Endeavour and Health Research funds. It ensures researchers have more control over the commercialisation of their inventions, with clear rules around ownership and equity sharing. https://lnkd.in/gipppFeD 47 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign i
Terms of Use - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Terms of Use Last Modified: August 20, 2024 Acceptance of the Terms of Use These terms of use are entered into by and between you and ThirdLaw Molecular Inc. for itself and on behalf of its affiliated companies, subsidiaries, and other affiliates (collectively the ”Company,” “we,” or “us”). The following terms and cond … r sole discretion. All changes are effective immediately when we post them, and apply to all access to and use of the Website thereafter. Your continued use of the Website following the posting of revised Terms of Use means that you accept and agree to the changes. You are expected to check this page so you are aware of any changes, as they are binding on you. Accessing the Website and Account Security We reserve the right to withdraw or amend this Website, and any service or … ctive features (collectively, “Interactive Services”) that allow users to post, submit, publish, display, or transmit to other users or other persons (hereinafter, “post”) content or materials (collectively, “User Contributions”) on or through the Website. All User Contributions must comply with the Content Standards set out in these Terms of Use. Any User Contribution you post to the site will be considered non-confidential and non-proprietary. By providing any User Contribu … ial and non-proprietary. By providing any User Contribution on the Website, you grant us and our affiliates and service providers, and each of their and our respective successors, and assigns the right to use, reproduce, modify, perform, display, distribute, and otherwise disclose to third parties any such material. You represent and warrant that: You own or control all rights in and to the User Contributions and have the right to grant the license granted above to us and our … erstand and acknowledge that you are responsible for any User Contributions you submit or contribute, and you, not the Company, have full responsibility for such content, including its legality, reliability, accuracy, and appropriateness. We are not responsible or liable to any third party for the content or accuracy of any User Contributions pos
Ladder Bio — Health funding & jobs | MapCo L Ladder Bio Health · Latest deal Nov 12 Get Free Analysis on 30+ AI Deals Daily Subscribe Free Read by strategy teams, founders, investors Search jobs board --> Deals ❤️ Jobs Find 30,000+ jobs at newly funded AI companies for your next opportunity. Browse jobs ↗ ladderbio.com LinkedIn More Health Selected Investors: Medical Excellence Capital , Hatch Biofund Latest Ladder Bio Signals Synthesising company profile Reading press coverage to extract founders, customers, traction signals and competitive positioning… Summary Ladder Bio Inc., formerly T
Ladder Bio | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Ladder Bio Ladder Bio Private Blue Bell, Pennsylvania Healthcare & Life Sciences https://ladderbio.com Last Round Seed Nov 12, 2025 Total Funding Raised $5.5M Momentum Score 75 /100 Company Overview Ladder Bio is a biotechnology company developing a novel therapeutic modality, Spiroligomer™ molecules, for targeted drug discovery. Sector Healthcare & Life Sciences Verticals Drug Discovery, Bi
%PDF-1.6 %���� 16464 0 obj > endobj 16486 0 obj >/Filter/FlateDecode/ID[ ]/Index[16464 60]/Info 16463 0 R/Length 115/Prev 27040017/Root 16465 0 R/Size 16524/Type/XRef/W[1 3 1]>>stream h�bbd```b`["�A$�:��� "9��� �;DrłH0;PD2��L���$c�N{���b�-�N�A��Z) ��QH�c�e`bdp�6��qX��]� `�� endstream endobj startxref 0 %%EOF 16523 0 obj >stream h��YyXSW�?�&�Bv�$,���d�V��"b�T�M�R���o�:�"�am@P�jA�C+�I]��e��6�:m����q:X ���tι7P����ɓ����y���$XU�n��^"��l��lf��)� ���|���� ����T��� � ��69�1yH�ɲhkr����ۀ���H���ŝ|� X@�,|ǥ���dthr 2�4� .6�|{�z &)C�#҆ #יHh rLr �" E H/$��i!| … �/��/fNMMݸqcFF�h�%x�b���ɓ�K�~���6l�����͝8q��V�S��}�葂�+WD*�)�yyy�M�>}����rfP$,G;�JKK��� cF?C�A��if�)I;�JJJJ���������$���7 � �(���睜�jjj؎��B�A� P�Ǐ x�� H1�� ;�f�E�A���C���\\\���������goo�v\o�� إ��(,,�������ĉjjj^^^l��H1B�������FGG���:::B ���N�>���RVVVSSS[[��;�I1���V# /^����f����588X[[{���7nTUUuww���ONN�jVUU566��Ů\��� ��� ^��� ����� @�!0�����:88��ۿ�����s���'O>}�T��b)�qHII��011����t�~�ŕ+W��G�5b)�Xk����3g����vD��E���*++?x��F; … ;���������˻ ��@z_���.��\� mc��f�EP��,���1��� U�h �����e�[ַic[���� ���rFp�U�ɩ \��Y�ֹV;. ��a -K�x/&���זx1�Yc���L�c(?�t��hڔ)} ���\�Y��£�}���i���F������;u��f�W�Z=��N &9$}�Dg�& &��y��7 5��J��6Z|�mV��9ğ��L�B=�q� z��`zV������ �$Q�B'��� '����qV`�^[8��==��0�Ӫ��G��r��BOjWS��5�Y�����H�6��d|���@�_x�ɒ�o �_\Z�`{�"IJȄ�@ |�)���q]?�n��ln��,�鮘�"P�eU��Q� pq�g��(�1>� �?��W�\�B��("�k�;K�������t�#hܸ# �#4�j�u ��l�����2��N9���g����B�d�S���E��s�S,��mt��?�m� … > �w� G÷9�5������/�S $3�D��6�f*���5��F����������W.k�9I+�η�Ɏ��Jȿ���:���L�]rfP�NkQ�}�� s���?|r�G����� W#_F̌'~l�*�E>��}�͜���sʼ��T@,����5w:H��mWL'*|�/�h�vc���w�Qnk���n��A�?��Ӣ~`G�{\��W�N���g��G��` � �8�9Ѓ��"y|o�bZ]諨},�C/�ߠ� ��3|T1��N;j?�.���B��ڍ�oBvo�ψ�r�Zm��'�{���l������g/xΟ�6�V��� �r��s��J�G����i[����� ���w�OKplB�Tpx�ޣ�,,��3^o>ؖ��:� ���YK[fߟnB~ �L��B;�v\c�+����(:�G� 1p�y �=�v�;��J�6�2�t�邆w� jgB�� d�@3�q��}�ڦ��3��'z}C�f#����q��s��?�̎� … dc4ff2-462e-4cea-b640-1199987e60aa uuid:7fe3dd9b-51bd-41d1-83f8-a4179bc610d9 44 application/pdf OHIO SPACE GRANT CONSORTIUM user Adobe PDF Library 15.0 D:20200804174850 OAI endstream endobj 4028 0 obj >stream hޜX�� 7 ���J|�nR�1�tA 1�4I'E�> �P��ޝQ�W�Y�stDR*�{K9k{�2�a�� ����i�č�EI���I�OKRe���V�]M=˴Zy"���MwX���#�f/:�i�Ht��\�i݄�4 P�L��v�5�p
Speaker Biographies | Discovery on Target | Sept 28-Oct 1, 2026 About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery Travel Posters Post … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press 2026 Speaker Biographies Warning! Web API Url is not set for the Speaker Bios. Speaker Biographies Filter by: Last Name Organization Program Clear Filters ‹ › × Chris Adams, CEO, Andarix Pharmaceuticals CEO Andarix Pharmaceuticals Christopher P. Adams is a seasoned life sciences entrepreneur and CEO with over … research and biomarker discovery. Today, Gali leverages this diverse toolkit to apply proteomics toward unlocking next-generation therapeutic opportunities in induced proximity modalities. Novel Drug Modalities Jordi Bach, PhD, Principal Scientist, Small Molecules Discovery & Dev, Almirall SA Principal Scientist Almirall SA Jordi Bach is a Principal Scientist in the Small Molecules Discovery & Development Department at Almirall. A synthetic organic chemist by training, he obt … . He is a 2021 recipient of the American Chemical Society’s Hero of Chemistry award for his leadership role in the discovery of Lorbrenaâ„¢ a macrocyclic inhibitor of mutant ALK kinase for the treatment of NSCLC. Novel Drug Modalities Todd Bayne, JD, Attorney, Intellectual Property, Medler Ferro Woodhouse & Mills PLLC Attorney Medler Ferro Woodhouse & Mills PLLC Todd Bayne Jr. is an Associate Attorney with Medler Ferro Woodhouse and Mills based in Northern Virginia, and foc … ional and high-quality potential clinical assets. He completed his postdoctoral fellowship at the Joslin Diabetes Center at Harvard University. He received PhD and MS degrees in pharmacology, cellular and molecular biology from Universite Nice-Sophia Antipolis, France. Innovative Discovery Technologies Shruthi Bharadwaj, PhD, Technical Staff, MIT
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
SEC Launches Cohort VI of Life Science Start-up Accelerator | Science Entrepreneur Club posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … s will take part in a fee-free, equity-free programme covering IP, fundraising, grant writing, pitching, investor introductions, specialist support, and access to the BioCapital Network - the UK’s largest life science investor community. Participants will also join SEC’s BioEntrepreneur Club and alumni network, where previous cohorts have collectively secured over £65M in funding. 👏 Diversity continues to be a priority, with 50% of companies across all six cohorts having a w … nnouncement of the Spain-Boston Biotech Initiative (SBBI) and its €200M venture fund marks a significant shift in how we approach biotech growth. This isn't just about capital infusion; it’s about building a high-speed corridor between Spanish innovation and the world’s premier biotech hub in Boston. In the clinical research landscape, we often see brilliant science hit a "glass ceiling" due to fragmented ecosystems. By providing Spanish startups with direct access to Boston’
Ladder Bio Launches With $5.5 Million Seed Financing And New Leadership VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Ladder Bio Launches With $5.5 Million Seed Financing And New Leadership By Amit Chowdhry • Nov 13, 2025 Ladder Bio Launches With $5.5 Million Seed Financing And New Leadership ThirdLaw Molecular has rebranded as Ladder Bio Inc., marking a pivotal step in its mission to pioneer Spiroligomer™ therapeutics, a novel class of ladder-shaped peptide-like molecules. The rebrand coincides with the closing of a $5.5 million Seed financing round led b
ThirdLaw Molecular Inc. Launches its Groundbreaking Platform for Targeted Drug Discovery with a 4.5-Billion Molecule DNA-Encoded Library of Spiroligomer™ Macromolecules - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy ThirdLaw Molecular Inc. Launches its Groundbreaking Platform for Targeted Drug Discovery with a 4.5-Billion Molecule DNA-Encoded Library of Spiroligomer™ Macromolec
News - Ladder Bio Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team News Contact Home Technology Spiroligomer™ Molecules Therapeutics Diagnostics Team Leadership Board of Directors News Contact Terms of Use Privacy Statement & Cookie Policy FCOI Policy Press Releases Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors May 19, 2026 Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform Blue Bell, Pa. — Ladder Bio, Inc., a structure-guided biotechnology company developing … Joins Dr. Tomi Sawyer as Scientific Advisor to ThirdLaw Molecular Jun 19, 2024 Award winning medicinal chemist, Dr. Joseph Vacca, joins Third Law Molecular LLC as Scientific Advisor, bringing deep drug discovery and development experience, to advance its groundbreaking new platform for targeted drug discovery. Joins Dr. Tomi Sawyer, Peptide Drug... read more Media Coverage June 25, 2026 Temple University spinout’s ‘Goldilocks molecules’ could change how we take our medicine